Use of Advisory Committees by the Food and Drug Administration: Hearings ... Ninety-third Congress Second Session [-Ninety-fourth Congress, First Session] ...U.S. Government Printing Office, 1974 |
From inside the book
Results 1-5 of 100
Page 4
... believe this is the first time you have had a chance to appear before this subcommittee . It is a pleasure for us to have you here . Mr. BROWN of Ohio . Let me also welcome Dr. Schmidt here . This is the first time we have him testify ...
... believe this is the first time you have had a chance to appear before this subcommittee . It is a pleasure for us to have you here . Mr. BROWN of Ohio . Let me also welcome Dr. Schmidt here . This is the first time we have him testify ...
Page 12
... believe , on the basis of experience , that these committees can materially expand the knowledge and judgment applied by the FDA to the broad range of areas for which we are responsible . This is not intended to deprecate the capability ...
... believe , on the basis of experience , that these committees can materially expand the knowledge and judgment applied by the FDA to the broad range of areas for which we are responsible . This is not intended to deprecate the capability ...
Page 67
... believe that the subject of these hearings is important and I would like to go through the statement and make a number of points . We believe that our use of advisory committees as well as outside consultants and experts do help us ...
... believe that the subject of these hearings is important and I would like to go through the statement and make a number of points . We believe that our use of advisory committees as well as outside consultants and experts do help us ...
Page 79
... believe , and correct me if I am wrong , that Mr. Goldhammer is an attorney . If he is , I will withdraw my statements . But there are some questions of law raised in this document and I am very concerned that it may be construed as an ...
... believe , and correct me if I am wrong , that Mr. Goldhammer is an attorney . If he is , I will withdraw my statements . But there are some questions of law raised in this document and I am very concerned that it may be construed as an ...
Page 80
... believe , Mr. Chairman , as an example that we did not accept roughly 20 percent of the National Academy of Science's recom- mendations with respect to its review of drug effectiveness . Mr. FOUNTAIN . Let me state this : As I ...
... believe , Mr. Chairman , as an example that we did not accept roughly 20 percent of the National Academy of Science's recom- mendations with respect to its review of drug effectiveness . Mr. FOUNTAIN . Let me state this : As I ...
Other editions - View all
Common terms and phrases
adequate advice Advisory Committee Act advisory committee meetings agency angina pectoris approval April 13 Apter basis Belton beta blockers BROWN of Ohio Bureau of Drugs carcinogenicity Cardiovascular Chairman clinical trials Commissioner committee members congestive heart failure consultants contraceptive controlled CROUT decision Depo Depo-Provera Devices diethylstilbestrol Director discussion doctors document dosage dose Drug Administration drug application Drug Products estrogens evaluation experts FDA staff FDA's Federal Advisory Committee Federal Register files Food and Drug FOUNTAIN going GOLDBERG GOLDHAMMER HUTT Inderal indication investigator issue judgment labeling marketed matter medical officers Medicine medroxyprogesterone acetate ment minutes mittee opinion package insert Panel on Review patients physician placebo postcoital contraceptive present problem propranolol protocol Provera question recommendations record regulatory Renal Advisory Committee response SCHMIDT scientific specific statement studies subcommittee submitted substantial evidence summary tion treatment verbatim transcript well-controlled
Popular passages
Page 555 - ... (6) personnel and medical files and similar files the disclosure of which would constitute a clearly unwarranted invasion of personal privacy; (7) investigatory files compiled for law enforcement purposes except to the extent available by law to a party other than an agency...
Page 79 - Secretary pursuant to subsection (b), do not include adequate tests by all methods reasonably applicable to show whether or not such drug is safe for use under the conditions prescribed, recommended, or suggested in the proposed labeling...
Page 555 - ... (5) inter-agency or intra-agency memorandums or letters which would not be available by law to a party other than an agency in litigation with the agency; (6) personnel and medical files and similar files the disclosure of which would constitute a clearly unwarranted invasion of personal privacy...
Page 79 - ... substantial evidence" means evidence consisting of adequate and well-controlled investigations, including clinical investigations, by experts qualified by scientific training and experience to evaluate the effectiveness of the drug involved, on the basis of which it could fairly and responsibly be concluded by such experts that the drug will have the effect it purports or is represented to have under the conditions of use prescribed, recommended, or suggested in the labeling or proposed labeling...
Page 549 - advisory committee" means any committee, board, commission, council, conference, panel, task force, or other similar group, or any subcommittee or other subgroup thereof...
Page 474 - Executive order; (2) related solely to the internal personnel rules and practices of an agency; (3) specifically exempted from disclosure by statute; (4) trade secrets and commercial or financial information obtained from a person and privileged or confidential...
Page 6 - FEDERAL ADVISORY COMMITTEE ACT FEDERAL ADVISORY COMMITTEE ACT PUBLIC LAW 92-463 AN ACT To authorize the establishment of a system governing the creation and operation of advisory committees in the executive branch of the Federal Government, and for other purposes.
Page 96 - Detailed minutes of each meeting of each advisory committee shall be kept and shall contain a record of the persons present, a complete and accurate description of matters discussed and conclusions reached, and copies of all reports received, issued, or approved by the advisory committee.
Page 79 - As used in this subsection and subsection (e), the term "substantial evidence" means evidence consisting of adequate and well-controlled investigations, including clinical investigations, by experts qualified by scientific training and experience to evaulate the effectiveness of the drug involved, on the basis of which it could fairly and responsibly be concluded by such experts that the drug will have the effect it purports or is represented to have under the conditions of use prescribed, recommended...
Page 290 - Secretary finds ( 1 ) that the applicant has failed to establish a system for maintaining required records, or has repeatedly or deliberately failed to maintain such records or to make required reports, in accordance with...